議程
Oncology Venture, Innovation & Partnering Summit 2024
2024年10月9-10日
Oncology Venture, Innovation & Partnering (VIP) Summit是一個有高級投資者、公司高管、企業家和商業領袖參加的特別活動。在輕鬆的人際交流環節中，您可以與未來的投資者和合作夥伴接觸。在行業主導的小組討論中，您將獲得關於癌症治療和診斷的資金籌集活動、目標和業務發展的戰略洞見。此外，在充滿活力的爐邊談話中，您還可以聽到腫瘤行業意見領袖的直率見解和商業建議，請您絕對不可錯過。
10月9日星期三
Registration Open
Capital Talks: Cracking the Code-Value Creation in Oncology Innovation
Gregory Grunberg, MD, MBA, Head, Life Sciences (North America), Temasek
What is the secret code for value creation in oncology innovation? Is it achieved by leveraging AI for care delivery or AI for drug discovery? Is it mechanism, stage, indication, or team? Drug or platform? Data or promise? Heavily capitalized or lean and mean? Do you go where the strategics are hunting or build it so they follow? Join 4 panelists who, through a capital market lens, help crack the code: how to create value in oncology innovation.
Michael Aberman, MD, General Partner, Regeneron Ventures
Jordan Bliss, Senior Managing Director, Guggenheim Partners
Luba Greenwood, Managing Partner, Binney Street Capital, Dana-Farber Cancer Institute
Amy Schulman, Managing Partner, Polaris Partners
BREAKOUT DISCUSSION:The BIOSECURE Act and Its Potential Implications
Matt Wetzel, Partner, Goodwin Procter LLP
The BIOSECURE Act is in the early stages of legislation in Congress. It is difficult to predict its final language; however, the fact that similar bills are receiving bipartisan support increases the potential likelihood of its passage into law. This panel will focus on whether oncology companies might consider updating (or implementing) processes for list-based screening of their counterparties (vendors, suppliers, partners) to ensure the prompt discovery and identification of potentially impacted entities.
Networking Refreshment Break
Sponsored Presentation (Opportunity Available)
Big Pharma's Outlook on Oncology Priorities for Partnering and M&A
Karen Hong, PhD, Former Partner, Novo Ventures; Co-Founder and Co-Owner, Cold Spring Bio
Marie-Claire Peakman, PhD, Partner, Pfizer Ventures; Executive Director, Worldwide Business Development, Pfizer
Venky Raghavan, PhD, Executive Director, Search & Evaluation - Oncology, Novartis
Hong Xin, PhD, Senior Director, Search & Evaluation, Johnson & Johnson
Welcome Reception
Close of Day
10月10日星期四
Registration and Morning Coffee
The Company Showcase provides 4 pioneering oncology companies with 7 minutes of main stage time to showcase their unique value proposition, business model, team leadership, and funding potential to senior-level investors, corporate executives, industry leaders, and partners in attendance.
Cancer Diagnostics, Screening, and Early Detection
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Join us for an insightful panel discussion on cancer diagnostics, screening, and early detection. Our panelists will explore the latest advancements in technology and methodologies, discuss the impact of early intervention on patient outcomes, and address current challenges in the field. Gain valuable knowledge on how cutting-edge innovations are shaping the future of cancer care and improving survival rates.
Lisa Alderson, CEO, Adela, Inc.
Anthony Chang, PhD, Founder & CEO, BAMF Health
Tom Miller, Founder & Managing Partner, GreyBird Ventures, LLC
Darshana Zaveri, Founder and Managing Partner, Catalyst Health Ventures
Networking Coffee Break
Roundtable Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing.
Emerging Oncology Therapeutics and Modalities
Derek DiRocco, PhD, Partner, RA Capital Management
The Oncology Venture, Innovation & Partnering Summit panel will focus on emerging oncology therapeutics and modalities. Oncology therapeutic development remains a pressing area of unmet need for patients and is perennially a high interest area for investors and strategics. We will tour the most compelling areas of the oncology therapeutic landscape, including radiopharmaceuticals, antibody drug conjugates, therapies targeting genetic drivers and synthetic lethality, as well as promising areas within immuno-oncology.
Christiana Bardon, MD, Co-Managing Partner, MPM BioImpact
Polly Brown, Vice President, Head of Business Development, Oncology R&D, AstraZeneca
Ryan B. Corcoran, MD, PhD, Director, Gastrointestinal Cancer Center Program; Scientific Director, Termeer Center for Targeted Therapy; Mark J. Kusek Endowed Chair in Colorectal Cancer, Massachusetts General Hospital Cancer Center; Associate Professor, Medicine, Harvard Medical School
Jeffrey Humphrey, MD, CMO, Lantheus
Networking Luncheon
Where Does Artificial Intelligence Add Value in Oncology? From Discovery to Care Delivery
Ben Freeberg, Founder and Managing Partner, Oncology Ventures
AI’s presence in oncology is undeniable, but its true impact depends on thoughtful integration. This panel examines how AI can be effectively woven into the cancer care continuum, from early drug discovery to clinical practice, ensuring that innovation translates into tangible benefits for clinicians, researchers, and patients.
Andrea Bild, PhD, Program Manager, Advanced Research Projects Agency for Health (ARPA-H)
Dan Caron, CEO, Health Universe
Selin Kurnaz, PhD, Co-Founder and CEO, Massive Bio
Tarun Mehra, Vice President, Healthcare Strategy & Partnerships, Microsoft
Ajit Singh, PhD, Partner, Artiman Ventures
Democratizing Access to Clinical Trials
Dave Stevenson, Managing Director, Merck Global Health Innovation Fund
Biopharma companies need more trial participants. Regulators and payers want more representative trial populations. Patient advocacy groups desire earlier and wider access to clinical trials. Are there ways to improve access to clinical trials in community settings? How can barriers to trial participation be reduced? Where speed is critical, how can access to innovative treatments be ensured on a timely basis? Are win-win approaches possible?
Manoja Lecamwasam, PhD, System Vice President, Intellectual Property and Life Sciences Innovation, CommonSpirit Health
Mark Lee, PhD, CEO & Co-Founder, N-Power Medicine
Carrie Williams, Vice President & Partner, McKesson Ventures
Networking Refreshment Break
Improving Oncology Care Delivery and Health Equity
Maya R. Said, ScD, Founder & CEO, Outcomes4Me
We are at a critical crossroad in cancer innovation: with more cancer drugs approved in the past 5 years than in the prior 15 years, and more than 50% of clinical trials focusing on cancer patients, how do we make sure we do not only improve outcomes for individual patients but also address rather than exacerbate disparities in cancer care? What needs to change to unlock the rapid dissemination of innovation and the development of the right therapies and technologies to address existing and emerging cancer disparities? This panel will discuss how technology, AI, novel care delivery models, evolving regulatory approaches, and new reimbursement and business models can drive guideline-concordant care, address cancer disparities and inequities, and unlock diversity in clinical trials. We will also explore the convergence of technology with value-based care and how improving the patient experience-in partnership with patients-can support health equity and improve patient outcomes for everyone.
Steven Isakoff, MD, PhD, Associate Director, Clinical Research, Mass General Cancer Center; Assistant Professor, Medicine, Harvard Medical School
Sean Khozin, MD, MPH, CEO, CEO Roundtable on Cancer and Project Data Sphere; Founder, Phyusion Bio; Research Affiliate, MIT
Dan Nardi, CEO, Reimagine Care
Chevon Rariy, MD, Chief Health Officer and Senior Vice President, Oncology Care Partners
Town Hall-Which Topics Are Front-of-Mind?
Luba Greenwood, Managing Partner, Binney Street Capital, Dana-Farber Cancer Institute
Karen Hong, PhD, Former Partner, Novo Ventures; Co-Founder and Co-Owner, Cold Spring Bio
Rachel Humphrey, MD, President and Founding CEO, Normunity
This interactive, engaging, and provocative session will explore topics that matter to you and your business. Our panel of industry veterans will share their ideas and points of view, but we want to hear from you! So please come ready to tee up issues you’d like to discuss and be prepared to engage with your peers as we efficiently unpack a variety of topics.
Closing Networking Reception
Close of Summit
* 活動內容有可能不事先告知作更動及調整。